5 recruiting, 4 active not recruiting, 2 completed, 2 terminated. 7 Phase 1, 5 Phase 2, 2 Early Phase 1, 2 Not applicable.
Follow this condition Literature Review of High Grade Ovarian Serous Adenocarcinoma trials Research Report on High Grade Ovarian Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High Definition Profiling of Ovarian Cancer Ascites Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma | Not yet recruiting | European Institute of Oncology | 50 | 2024-11-01 | 2024-11-20 | |
| This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors ZM008 - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Zumutor Biologics Inc. | 100 | 2024-05-22 | 2026-04-02 |
| Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer Niraparib - Ovarian Cancer, Stage III Ovarian Cancer | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 40 | 2023-08-21 | 2023-11-22 |
| Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer Modi-1 Moditope, Pembrolizumab, MicronJet600™ microneedle device (NanoPass) - Triple Negative Breast Cancer, Renal Cell Cancer | Phase 1 / Phase 2 | Recruiting | Scancell Ltd | 168 | 2022-04-07 | 2025-09-17 |
| Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients Lenvatinib, Pembrolizumab - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-11-09 | 2026-08-10 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer Uterine lavage, or a wash of the womb, Blood sample, Pap smear - Ovarian Neoplasms, Ovarian Epithelial Carcinoma | Recruiting | Massachusetts General Hospital | 250 | 2020-04-13 | 2025-09-16 | |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Chemotherapy, Olaparib, Therapeutic Conventional Surgery - BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-06-07 | 2026-08-12 |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Copanlisib, Niraparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2019-04-29 | 2026-07-23 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
| Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer Biospecimen Collection, Laboratory Biomarker Analysis, Lavage - High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8 | Not applicable | Terminated | University of Washington | 52 | 2018-11-16 | 2024-01-17 |
| Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) Birinapant, Carboplatin, Laboratory Biomarker Analysis - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-08-01 | 2025-05-13 | |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, BMN 673 - Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 4 | 2015-06-02 | 2022-02-24 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC WGS and RNA sequencing, circulating tumor DNA (ctDNA), FDG PET/CT imaging - High Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma | Not applicable | Recruiting | Turku University Hospital | 200 | 2012-02-01 | 2025-01-16 |
Ovarian Neoplasms (11) · Fallopian Tube Neoplasms (7) · Triple Negative Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Ascites (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Disease Progression (1)
Neoplasms by Site (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genital Diseases (13) · Neoplasms (13) · Adnexal Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Gonadal Disorders (11) · Ovarian Diseases (10) · Fallopian Tube Diseases (7)
olaparib (3) · Papanicolaou Test (2) · niraparib (2) · pembrolizumab (2) · Antibodies (1) · Blood Specimen Collection (1) · Carboplatin (1) · Circulating Tumor DNA (1) · Cyclophosphamide (1) · Drug Therapy (1) · Ipilimumab (1) · Nivolumab (1) · Sequence Analysis, RNA (1) · Therapeutic Irrigation (1) · Vaginal Smears (1)
M.D. Anderson Cancer Center (5) · European Institute of Oncology (1) · Jonsson Comprehensive Cancer Center (1) · Massachusetts General Hospital (1) · Scancell Ltd (1) · Sunnybrook Health Sciences Centre (1) · TCR2 Therapeutics (1) · Turku University Hospital (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1) · Zumutor Biologics Inc. (1)
United States (11) · Canada (2) · Finland (1) · Italy (1) · United Kingdom (1)
Shannon N Westin (3) · Amir A Jazaeri (1) · Barbara S. Norquist (1) · Christian Ottensmeier, MD (1) · Christos Patriotis, PhD (1) · Dr. Allan Covens, MD (1) · Giuseppe Testa (1) · Johanna Hynninen, MD, PhD (1) · Jyotsna Fuloria (1) · Maloy Ghosh, PhD (1) · Marta Crispens, MD (1) · Rosana Risques (1) · Sampsa Hautaniemi, DTech, Prof (1) · Sanaz Memarzadeh (1) · Shannon Westin (1)
PMID 32379297, PMID 37207655, PMID 37501016, PMID 38176019, PMID 40885189, PMID 41528970
P50CA083639 (2), P30CA016672 (1), U01CA152990 (1), U2CCA271871 (1)